Keynote:
Prevention Guidelines: Where Do We Stand?

Cardiology Updates
Boston, Massachusetts
September 18, 2013

Content Collaborator
Session 1: Keynote: Prevention Guidelines: Where Do We Stand?

Learning Objectives

1. Identify how to incorporate the best current evidence regarding cardiovascular prevention effectively into clinical practice.
2. Evaluate how to approach the management of lipids and blood pressure in 2013.

Faculty

Peter Libby, MD, FACC  
Chief, Cardiovascular Medicine  
Brigham and Women's Hospital  
Mallinckrodt Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts

Dr Peter Libby is chief of cardiovascular medicine at the Brigham and Women’s Hospital (BWH) in Boston. He also serves as the Mallinckrodt Professor of Medicine at Harvard Medical School, where he directs the DW Reynolds Cardiovascular Clinical Research Center. His current research focus is the role inflammation plays in vascular diseases such as atherosclerosis. His areas of clinical expertise include general and preventive cardiology.

Dr Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now the BWH). He has received recognition and numerous awards for his research accomplishments, including the 2006 Distinguished Scientist Award of the American College of Cardiology. He also holds an honorary Master of Arts from Harvard University.

An author and lecturer on cardiovascular medicine and atherosclerosis, Dr Libby has published extensively in medical journals, including Circulation, the Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, the New England Journal of Medicine, and Nature. He is editor in chief of the new ninth edition of Braunwald’s Heart Disease. Dr Libby has also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to Harrison’s Principles of Internal Medicine. He has frequently served as a consultant to the National Heart, Lung, and Blood Institute; including a 5 year term on its Board of Scientific Councilors and was the recipient of the organization’s MERIT Award. Dr Libby has held numerous visiting professorships and has been selected to deliver over fifty named or keynote lectures throughout the world.

Dr Libby's professional memberships include the Association of American Physicians, the American Society for Clinical Investigation, and honorary membership in the British Atherosclerosis Society. The current president of the Association of University Cardiologists, Dr Libby has served in many roles as a volunteer for the American Heart Association, including chairman of several research committees and member of executive committee councils on arteriosclerosis, circulation, and basic science.

Faculty Financial Disclosure Statement

The presenting faculty reports the following:

Dr Libby is a scientific advisory board member for Athera Biotechnologies, BIND Biosciences, Carolus Therapeutics, and Interleukin Genetics. He also serves as an unpaid consultant and/or is involved in clinical trials with Amgen; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pronova BioPharma; and Sigma-Tau Pharmaceuticals, Inc.
Suggested Reading List


